Back to top
more

Dynavax Technologies (DVAX)

(Delayed Data from NSDQ)

$10.07 USD

10.07
2,997,469

-0.46 (-4.37%)

Updated Aug 5, 2024 04:00 PM ET

After-Market: $10.08 +0.01 (0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Dynavax (DVAX) Gains on Clover's COVID-19 Vaccine Study Data

by Zacks Equity Research

Dynavax (DVAX) stock gains as partner Clover announces strong efficacy of its COVID-19 vaccine candidate against the Delta variant in pivotal study data readout.

Dynavax (DVAX) Gains as Medigen Rolls Out COVID-19 Vaccine

by Zacks Equity Research

Dynavax (DVAX) stock gains as partner Medigen announces launch of its COVID-19 vaccine MVC-COV1901 adjuvanted with CpG 1018 of the former.

Dynavax Technologies (DVAX) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 150.00% and 19.82%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

What's in the Cards for Amarin (AMRN) This Earnings Season?

by Zacks Equity Research

Amarin's (AMRN) second-quarter results are likely to reflect recovery in Vascepa sales amid potential recovery in COVID-19 related disruptions.

Is a Beat Likely for Moderna (MRNA) This Earnings Season?

by Zacks Equity Research

Investors are likely to focus on any updated outlook for Moderna's (MRNA) authorized coronavirus vaccine, on the second-quarter earrings call.

Bionano (BNGO) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Bionano Genomics (BNGO) is likely to provide updates on earnings and revenues when it reports second-quarter 2021 results.

Dynavax Technologies (DVAX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Dynavax Technologies (DVAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Dynavax Technologies (DVAX) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 150.00% and 37.94%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Dynavax Technologies (DVAX) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Dynavax (DVAX) Up on Positive COVID-19 Vaccine Study Data (Revised)

by Zacks Equity Research

Dynavax's (DVAX) partner Valneva, developing a COVID-19 vaccine using Dynavax's adjuvant, reports 100% seroconversion rates from a phase I/II study.

Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates

by Zacks Equity Research

The biotech sector was in focus last week with regulatory updates from Acadia (ACAD) and vaccine updates from quite a few companies like Emergent (EBS), among others.

Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates

by Zacks Equity Research

The biotech sector was in focus last week with regulatory updates from Acadia (ACAD) and vaccine updates from quite a few companies like Emergent (EBS), among others.

Dynavax (DVAX) Up on Positive COVID-19 Vaccine Study Data

by Zacks Equity Research

Dynavax's (DVAX) partner Valneva, developing a COVID-19 vaccine using Dynavax's adjuvant, reports 100% seroconversion rates from a phase I/II study.

Endo's (ENDP) Earnings & Revenues Surpass Estimates in Q4

by Zacks Equity Research

Endo's (ENDP) earnings and sales beat estimates in the fourth quarter.

Bausch's (BHC) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Bausch (BHC) reports better-than-expected results for the fourth quarter as the business shows recovery signs from the COVID-19 pandemic.

Global Blood (GBT) Q4 Earnings Miss, Revenues Beat Estimates

by Zacks Equity Research

Global Blood (GBT) reports a wider-than-expected loss in the fourth quarter of 2020 while revenues beat estimates.

ACADIA (ACAD) Beats on Q4 Earnings, Misses on Revenues

by Zacks Equity Research

ACADIA's (ACAD) loss narrows in the fourth quarter of 2020 while it misses estimates for revenues. Nuplazid drives year-over-year revenues.

Repligen (RGEN) Q4 Earnings & Sales Top, 2021 Outlook Bright

by Zacks Equity Research

Repligen (RGEN) reports encouraging fourth-quarter results with sales and earnings beating estimates. The company's guidance for 2021 also beats market expectations. Stock up.

Has Dynavax Technologies (DVAX) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (DVAX) Outperforming Other Medical Stocks This Year?

Arena (ARNA) Q4 Earnings Miss Estimates, Pipeline Progresses

by Zacks Equity Research

Arena Pharmaceuticals (ARNA) misses bottom-line estimates for fourth-quarter 2020. It initiates new study to evaluate etrasimod in patients with eosinophilic esophagitis.

Viatris (VTRS) Declines on Lackluster Outlook, Announces Dividend

by Zacks Equity Research

Viatris (VTRS) declines after it announces outlook for 2021 and reaffirms strategic commitments.

Dynavax Technologies (DVAX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Dynavax Technologies (DVAX) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Dynavax Technologies (DVAX) closed the most recent trading day at $9.82, moving +0.41% from the previous trading session.

Moving Average Crossover Alert: Dynavax (DVAX)

by Zacks Equity Research

Dynavax Technologies (DVAX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Dynavax Technologies (DVAX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 25.00% and 21.89%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?